Liquidia Corp Chief Business Officer Jason Adair sold 688 shares of common stock. The open-market sale on April 27, 2026 was executed at $41.65 per share pursuant to a Rule 10b5-1 trading plan and was used to cover taxes from the settlement of restricted stock units. Following the transaction, Adair directly holds 214,738 shares, along with multiple grants of unvested RSUs and shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia Corporation uses its 2026 proxy to highlight a breakthrough year driven by the launch of YUTREPIA, which generated hundreds of millions in net product sales and carried the company to profitability within four months. The company ended the year with $190.7 million in cash and positive cash flow. Management describes a large opportunity in prostacyclin therapies, citing over $4.5 billion in branded sales across PAH and PH-ILD, with treprostinil formulations at about $2.9 billion and roughly 60,000 addressable PH-ILD patients, most still untreated. Liquidia plans six new clinical studies in 2026 to strengthen YUTREPIA’s profile, advance its L606 inhaled treprostinil candidate into a pivotal Phase 3 RE-SPIRE study, and explore new indications. The proxy also asks stockholders to elect three Class II directors, ratify PricewaterhouseCoopers LLP as auditor, and approve an advisory vote on executive compensation at a fully virtual June 16, 2026 annual meeting.
Liquidia Corp Chief Executive Officer–associated entity sells shares under pre-planned plan. An entity managed by CEO Roger Jeffs, Serendipity BioPharma LLC, sold 18,839 shares of Liquidia common stock on April 17, 2026 at a volume-weighted average price of $40.6049 per share, with individual trades between $40.00 and $41.85.
After the sale, Serendipity BioPharma LLC held 1,423,095 shares indirectly for Jeffs, while he also held 1,137,599 shares directly and 46,595 shares through a living trust. Footnotes state the trade was effected under a Rule 10b5-1 trading plan adopted on November 5, 2025, and Jeffs also has several tranches of unvested restricted stock units.
Serendipity Biopharma (LQDA) reported multiple Form 144 sale notifications showing controlled sales of common stock by related parties. The excerpt lists scheduled 10b5-1 sales and an individual sale, including 25,000 shares on 04/16/2026 for $1,007,800 and 32,744 shares on 04/13/2026 for $1,256,387.28. The filings identify 10b5-1 plan activity and a sale attributed to Roger Jeffs; timing and plan mechanics are shown by sale dates in April 2026.
Liquidia Corp Chief Executive Officer Roger Jeffs reported open-market sales of company common stock through entities he controls. On April 16 he sold 25,000 shares at an average price of $40.312, on April 15 another 25,000 shares at $40.1409, and on April 14 3,300 shares at $40.00, totaling 53,300 shares sold. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025. After these transactions, Jeffs’ indirect holdings were 1,441,934 shares, alongside 1,137,599 shares held directly and 46,595 shares held indirectly through Serendipity BioPharma LLC, plus substantial unvested restricted stock units.
Liquidia Corp CFO and COO Michael Kaseta reported option exercises and share sales in April 2026. He exercised incentive stock options to acquire a total of 89,971 shares of common stock at an exercise price of $2.79 per share, from options that were fully vested as of November 30, 2024.
Kaseta then sold an aggregate 142,390 shares of common stock in open-market transactions on April 14–15, 2026 at prices including $40.00 and a volume‑weighted average price of $40.1409, within a range of $40.00 to $40.39. These sales were made under a Rule 10b5‑1 trading plan adopted on November 5, 2025. Following the transactions, he directly holds 353,356 shares of common stock, plus additional unvested RSUs and ESPP shares noted in the footnotes.
Serendipity BioPharma LLC and related parties reported multiple resale transactions of restricted common stock of LQDA. The excerpt lists sales including 04/16/2026 entries for 25,000 shares (proceeds $1,003,000.00) and earlier 10b5-1 sales on 04/15/2026 (25,000 shares, $1,003,522.50), 04/14/2026 (3,300 shares, $132,000.00), and other dated entries. The records identify Roger Jeffs as a reporting party for a 04/13/2026 sale of 32,744 shares (proceeds $1,256,387.28).
Serendipity Biopharma filed a Form 144 disclosing recent resale activity under 10b5-1 plans. The excerpt lists four sales: 3,300 shares on 04/14/2026 for $132,000; 32,744 shares on 04/13/2026 for $1,256,387.28; 21,433 shares on 04/10/2026 for $859,876.96; and 25,000 shares on 04/09/2026 for $1,002,887.50.
Michael Kaseta filed a Form 144 reporting proposed sales of Common Stock on 04/15/2026. The filing lists 86,971 shares from an Exercise of Stock Options, 9,044 shares from an Employee Stock Purchase Plan, and 43,375 shares from Restricted Stock Units. The form also summarizes recent 10b5-1 sales, including 133,789 shares on 04/09/2026, 23,821 shares on 04/10/2026, 18,958 shares on 04/13/2026, and 3,000 shares on 04/14/2026, with individual proceeds shown in the filing.